(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN) announced a significant milestone with a USD 1.25 million payment triggered by the…
(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN) has announced that its partner Knight Therapeutics Inc. (TSX: GUD) exceeded the sales…
(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company dedicated to addressing severe bacterial and fungal infections, has announced that its…
(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company specializing in severe bacterial and fungal infection treatments, has announced robust financial…
BASEL, 11-Dec-2018 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the sales of the antifungal Cresemba® (isavuconazole) by Astellas…